Li Zuo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Li Zuo has a total of 98 co-authors. Here are the top co-authors by number of shared publications:
Li Zhang
Department of Urology, The Affiliated Changzhou Second People’s Hospital of Nanjing Medical University, Changzhou, China
4 shared publicationsLifeng Zhang
Department of Urology, The Affiliated Changzhou Second People’s Hospital of Nanjing Medical University, Changzhou, China
4 shared publicationsXiaokai Shi
Department of Urology The Third Affiliated Hospital of Nanjing Medical University (Changzhou Second People's Hospital) Changzhou China
4 shared publications- Yuanyuan Mi
Department of Urology Affiliated Hospital of Jiangnan University Wuxi China
4 shared publications Lei Gao
Department of Urology, Changzhou Second People's Hospital, Changzhou Medical Center, Nanjing Medical University, Changzhou, 213003, Jiangsu Province, PR China
3 shared publicationsLei Zhang
Department of Urology The Second People's Hospital of Changzhou, Changzhou Medical Center Changzhou China
3 shared publications
Latest Publications
- Open Access
- 17 April 2026
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 30 (8) , e71147
ARIH2 Ubiquitination Regulates NUPR1 to Inhibit Ferroptosis in Bladder Cancer
NUPR1 is a pro‐tumorigenic factor in bladder cancer (BLCA), but the mechanisms governing its protein stability remain poorly defined. Here, we identified ARIH2 as an E3 ubiquitin ligase that interacts with NUPR1 in BLCA cells through immunoprecipitation‐mass spectrometry (IP‐MS), co‐immunoprecipitation (Co‐IP), and immunofluorescence analyses. ARIH2 overexpression reduced NUPR1 abundance and inhibited BLCA cell proliferation and migration while enhancing apoptosis, whereas ARIH2 knockdown increased NUPR1 expression and promoted malignant phenotypes. Mechanistically, ARIH2 depletion prolonged NUPR1 protein stability and reduced its ubiquitination, indicating that ARIH2 negatively regulates NUPR1 through ubiquitin‐mediated degradation. Moreover, NUPR1 overexpression suppressed ferroptosis, as reflected by increased GPX4 and SLC7A11, decreased ACSL4, reduced lipid peroxidation, and diminished Fe 2+ accumulation, while NUPR1 knockdown exerted the opposite effects. ARIH2 knockdown mimicked the ferroptosis‐resistant phenotype induced by NUPR1 upregulation, supporting that ARIH2 modulates ferroptosis through NUPR1. Bioinformatic and experimental analyses further showed that NUPR1 was associated with immunosuppressive infiltration and promoted M2 macrophage polarization. Together, our findings uncover an ARIH2–NUPR1 regulatory axis that drives BLCA progression by suppressing ferroptosis and favouring an immunosuppressive microenvironment, highlighting this pathway as a potential therapeutic target in BLCA.
- 17 April 2026
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 30 (8) , e71147
Open AccessARIH2 Ubiquitination Regulates NUPR1 to Inhibit Ferroptosis in Bladder Cancer
NUPR1 is a pro‐tumorigenic factor in bladder cancer (BLCA), but the mechanisms governing its protein stability remain poorly defined. Here, we identified ARIH2 as an E3 ubiquitin ligase that interacts with NUPR1 in BLCA cells through immunoprecipitation‐mass spectrometry (IP‐MS), co‐immunoprecipitation (Co‐IP), and immunofluorescence analyses. ARIH2 overexpression reduced NUPR1 abundance and inhibited BLCA cell proliferation and migration while enhancing apoptosis, whereas ARIH2 knockdown increased NUPR1 expression and promoted malignant phenotypes. Mechanistically, ARIH2 depletion prolonged NUPR1 protein stability and reduced its ubiquitination, indicating that ARIH2 negatively regulates NUPR1 through ubiquitin‐mediated degradation. Moreover, NUPR1 overexpression suppressed ferroptosis, as reflected by increased GPX4 and SLC7A11, decreased ACSL4, reduced lipid peroxidation, and diminished Fe 2+ accumulation, while NUPR1 knockdown exerted the opposite effects. ARIH2 knockdown mimicked the ferroptosis‐resistant phenotype induced by NUPR1 upregulation, supporting that ARIH2 modulates ferroptosis through NUPR1. Bioinformatic and experimental analyses further showed that NUPR1 was associated with immunosuppressive infiltration and promoted M2 macrophage polarization. Together, our findings uncover an ARIH2–NUPR1 regulatory axis that drives BLCA progression by suppressing ferroptosis and favouring an immunosuppressive microenvironment, highlighting this pathway as a potential therapeutic target in BLCA.
- Open Access
- 13 June 2025
- Published by Springer Nature in npj Precision Oncology
- Vol. 9 (1) , 1-16
Gαi3: a crucial biomarker and therapeutic target in bladder cancer
This study investigates the role of Gαi3 in bladder cancer, focusing on its expression, functions, and mechanisms. Bioinformatics reveal that Gαi3 is overexpressed in bladder cancer, linked to poorer survival and higher tumor grades. Single-cell sequencing data confirm Gαi3 overexpression in bladder cancer epithelial cells. Additionally, Gαi3 is upregulated in tissues from locally treated patients and various bladder cancer cells. Silencing Gαi3 with targeted shRNA inhibited cell proliferation, migration, and invasion, activating caspase-mediated apoptosis. CRISPR/Cas9-mediated knockout of Gαi3 also exhibited significant anti-cancer effects, while overexpression enhanced cell proliferation and mobility. Gαi3 activates the Akt-mTOR pathway; silencing or knockout reduced phosphorylation of Akt and S6K, while overexpression increased it. The anti-cancer effects of Gαi3 shRNA were lessened by reactivating Akt-mTOR with a constitutively active Akt1 mutant. We observed a stronger binding affinity between the Gαi3 promoter and the transcription factor GATA4 in bladder cancer tissues. GATA4 silencing lowered Gαi3 expression, while GATA4 overexpression increased it. In vivo, Gαi3 silencing significantly hindered the growth of bladder cancer xenografts in nude mice, along with inactivation of the Akt-mTOR pathway and increased apoptosis. These results highlight Gαi3’s functional role in bladder cancer progression.
- 13 June 2025
- Published by Springer Nature in npj Precision Oncology
- Vol. 9 (1) , 1-16
Open AccessGαi3: a crucial biomarker and therapeutic target in bladder cancer
This study investigates the role of Gαi3 in bladder cancer, focusing on its expression, functions, and mechanisms. Bioinformatics reveal that Gαi3 is overexpressed in bladder cancer, linked to poorer survival and higher tumor grades. Single-cell sequencing data confirm Gαi3 overexpression in bladder cancer epithelial cells. Additionally, Gαi3 is upregulated in tissues from locally treated patients and various bladder cancer cells. Silencing Gαi3 with targeted shRNA inhibited cell proliferation, migration, and invasion, activating caspase-mediated apoptosis. CRISPR/Cas9-mediated knockout of Gαi3 also exhibited significant anti-cancer effects, while overexpression enhanced cell proliferation and mobility. Gαi3 activates the Akt-mTOR pathway; silencing or knockout reduced phosphorylation of Akt and S6K, while overexpression increased it. The anti-cancer effects of Gαi3 shRNA were lessened by reactivating Akt-mTOR with a constitutively active Akt1 mutant. We observed a stronger binding affinity between the Gαi3 promoter and the transcription factor GATA4 in bladder cancer tissues. GATA4 silencing lowered Gαi3 expression, while GATA4 overexpression increased it. In vivo, Gαi3 silencing significantly hindered the growth of bladder cancer xenografts in nude mice, along with inactivation of the Akt-mTOR pathway and increased apoptosis. These results highlight Gαi3’s functional role in bladder cancer progression.
- 16 August 2024
- Published by Wiley in Journal of Cellular Physiology
- Vol. 239 (11) , e31412
Mechanistic study of NUPR1 in bladder cancer development through transcriptional regulation of CCR2
Nuclear protein‐1 (NUPR1) (also known as p8) is one of the genes associated with transcription factors that participate in various aspects of cancer initiation and development. However, the molecular mechanisms of NUPR1 in bladder cancer (BLCA) remain unclear. We conducted an analysis of the correlation between NUPR1 expression and related genes using the Gene Expression Omnibus (GEO) online database. We employed lentivirus‐mediated small interfering RNA (siRNA) to knockdown the expression of NUPR1 in two human BLCA cell lines. In vitro experiments were conducted to validate the impact of NUPR1 interference on BLCA and the influence of NUPR1 on the transcription of chemokine receptor‐2 (CCR2). Furthermore, transcription factors for CCR2 were predicted using the PROMO database. Co‐immunoprecipitation (Co‐IP) and immunofluorescence double staining were used to detect the binding between NUPR1 and CCAAT/enhancer binding protein γ (CEBPG). In vivo and in vitro experiments were conducted to validate that NUPR1 regulates CCR2 transcription through CEBPG. In vitro experiments indicate that the suppression of NUPR1 inhibited BLCA growth. Analysis of the GEO database revealed a positive correlation between the expression of NUPR1 and CCR2. Luciferase experiments confirmed that NUPR1 influences the transcription of CCR2. Online data indicates that CEBPG is a transcription factor for CCR2. Co‐IP and immunofluorescence double staining confirmed binding between NUPR1 and CEBPG. Luciferase assays and chromatin immunoprecipitation (ChIP) demonstrate that CEBPG regulates the transcription of CCR2. Additionally, rescue experiments at the cellular level and animal experiments validated the aforementioned mechanism. NUPR1 promotes a promotional role in BLCA, and interference with NUPR1 can inhibit the proliferation and invasive abilities of BLCA. There was a correlation between the expressions of NUPR1 and CCR2, and NUPR1 binds with CEBPG in the cell nucleus. Transcriptional regulation of CCR2 by NUPR1 may be achieved through the involvement of CEBPG.
- 16 August 2024
- Published by Wiley in Journal of Cellular Physiology
- Vol. 239 (11) , e31412
Mechanistic study of NUPR1 in bladder cancer development through transcriptional regulation of CCR2
Nuclear protein‐1 (NUPR1) (also known as p8) is one of the genes associated with transcription factors that participate in various aspects of cancer initiation and development. However, the molecular mechanisms of NUPR1 in bladder cancer (BLCA) remain unclear. We conducted an analysis of the correlation between NUPR1 expression and related genes using the Gene Expression Omnibus (GEO) online database. We employed lentivirus‐mediated small interfering RNA (siRNA) to knockdown the expression of NUPR1 in two human BLCA cell lines. In vitro experiments were conducted to validate the impact of NUPR1 interference on BLCA and the influence of NUPR1 on the transcription of chemokine receptor‐2 (CCR2). Furthermore, transcription factors for CCR2 were predicted using the PROMO database. Co‐immunoprecipitation (Co‐IP) and immunofluorescence double staining were used to detect the binding between NUPR1 and CCAAT/enhancer binding protein γ (CEBPG). In vivo and in vitro experiments were conducted to validate that NUPR1 regulates CCR2 transcription through CEBPG. In vitro experiments indicate that the suppression of NUPR1 inhibited BLCA growth. Analysis of the GEO database revealed a positive correlation between the expression of NUPR1 and CCR2. Luciferase experiments confirmed that NUPR1 influences the transcription of CCR2. Online data indicates that CEBPG is a transcription factor for CCR2. Co‐IP and immunofluorescence double staining confirmed binding between NUPR1 and CEBPG. Luciferase assays and chromatin immunoprecipitation (ChIP) demonstrate that CEBPG regulates the transcription of CCR2. Additionally, rescue experiments at the cellular level and animal experiments validated the aforementioned mechanism. NUPR1 promotes a promotional role in BLCA, and interference with NUPR1 can inhibit the proliferation and invasive abilities of BLCA. There was a correlation between the expressions of NUPR1 and CCR2, and NUPR1 binds with CEBPG in the cell nucleus. Transcriptional regulation of CCR2 by NUPR1 may be achieved through the involvement of CEBPG.
- Open Access
- 11 March 2024
- Published by Springer Nature in Cell Death & Disease
- Vol. 15 (3) , 1-14
A first-in-class TIMM44 blocker inhibits bladder cancer cell growth
Mitochondria play a multifaceted role in supporting bladder cancer progression. Translocase of inner mitochondrial membrane 44 (TIMM44) is essential for maintaining function and integrity of mitochondria. We here tested the potential effect of MB-10 (MitoBloCK-10), a first-in-class TIMM44 blocker, against bladder cancer cells. TIMM44 mRNA and protein expression is significantly elevated in both human bladder cancer tissues and cells. In both patient-derived primary bladder cancer cells and immortalized (T24) cell line, MB-10 exerted potent anti-cancer activity and inhibited cell viability, proliferation and motility. The TIMM44 blocker induced apoptosis and cell cycle arrest in bladder cancer cells, but failed to provoke cytotoxicity in primary bladder epithelial cells. MB-10 disrupted mitochondrial functions in bladder cancer cells, causing mitochondrial depolarization, oxidative stress and ATP reduction. Whereas exogenously-added ATP and the antioxidant N-Acetyl Cysteine mitigated MB-10-induced cytotoxicity of bladder cancer cells. Genetic depletion of TIMM44 through CRISPR-Cas9 method also induced robust anti-bladder cancer cell activity and MB-10 had no effect in TIMM44-depleted cancer cells. Contrarily, ectopic overexpression of TIMM44 using a lentiviral construct augmented proliferation and motility of primary bladder cancer cells. TIMM44 is important for Akt-mammalian target of rapamycin (mTOR) activation. In primary bladder cancer cells, Akt-S6K1 phosphorylation was decreased by MB-10 treatment or TIMM44 depletion, but enhanced after ectopic TIMM44 overexpression. In vivo, intraperitoneal injection of MB-10 impeded bladder cancer xenograft growth in nude mice. Oxidative stress, ATP reduction, Akt-S6K1 inhibition and apoptosis were detected in MB-10-treated xenograft tissues. Moreover, genetic depletion of TIMM44 also arrested bladder cancer xenograft growth in nude mice, leading to oxidative stress, ATP reduction and Akt-S6K1 inhibition in xenograft tissues. Together, targeting overexpressed TIMM44 by MB-10 significantly inhibits bladder cancer cell growth in vitro and in vivo.
- 11 March 2024
- Published by Springer Nature in Cell Death & Disease
- Vol. 15 (3) , 1-14
Open AccessA first-in-class TIMM44 blocker inhibits bladder cancer cell growth
Mitochondria play a multifaceted role in supporting bladder cancer progression. Translocase of inner mitochondrial membrane 44 (TIMM44) is essential for maintaining function and integrity of mitochondria. We here tested the potential effect of MB-10 (MitoBloCK-10), a first-in-class TIMM44 blocker, against bladder cancer cells. TIMM44 mRNA and protein expression is significantly elevated in both human bladder cancer tissues and cells. In both patient-derived primary bladder cancer cells and immortalized (T24) cell line, MB-10 exerted potent anti-cancer activity and inhibited cell viability, proliferation and motility. The TIMM44 blocker induced apoptosis and cell cycle arrest in bladder cancer cells, but failed to provoke cytotoxicity in primary bladder epithelial cells. MB-10 disrupted mitochondrial functions in bladder cancer cells, causing mitochondrial depolarization, oxidative stress and ATP reduction. Whereas exogenously-added ATP and the antioxidant N-Acetyl Cysteine mitigated MB-10-induced cytotoxicity of bladder cancer cells. Genetic depletion of TIMM44 through CRISPR-Cas9 method also induced robust anti-bladder cancer cell activity and MB-10 had no effect in TIMM44-depleted cancer cells. Contrarily, ectopic overexpression of TIMM44 using a lentiviral construct augmented proliferation and motility of primary bladder cancer cells. TIMM44 is important for Akt-mammalian target of rapamycin (mTOR) activation. In primary bladder cancer cells, Akt-S6K1 phosphorylation was decreased by MB-10 treatment or TIMM44 depletion, but enhanced after ectopic TIMM44 overexpression. In vivo, intraperitoneal injection of MB-10 impeded bladder cancer xenograft growth in nude mice. Oxidative stress, ATP reduction, Akt-S6K1 inhibition and apoptosis were detected in MB-10-treated xenograft tissues. Moreover, genetic depletion of TIMM44 also arrested bladder cancer xenograft growth in nude mice, leading to oxidative stress, ATP reduction and Akt-S6K1 inhibition in xenograft tissues. Together, targeting overexpressed TIMM44 by MB-10 significantly inhibits bladder cancer cell growth in vitro and in vivo.
- Open Access
Impact of the cytotoxic T-lymphocyte associated antigen-4 rs231775 A/G polymorphism on cancer risk
- Open Access
- 5 October 2023
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 28 (5)
Identification of hub genes in bladder transitional cell carcinoma through ceRNA network construction integrated with gene network analysis
Bladder transitional cell carcinoma (BTCC) forms more than 90% of bladder cancer cases. It brings challenges to the early diagnosis and therapy of BTCC, due to lack of efficient screening biomarkers. We used weighted gene co‐expression network analysis (WGCNA) combined competing endogenous RNA (ceRNA) network construction depending on TCGA datasets to investigate potential hub genes and regulatory pathways associated with occurrence and progression of BTCC. We further used real‐time polymerase chain reaction (RT‐PCR) to validate the relative expression genes correlated with BTCC. By WGCNA, the gene co‐expression module with 11 genes was found corelated with BTCC tumour stage and prognosis after survival analyses. Ultimately, we put 100 highly stage‐related genes into the above constructed ceRNA network and then constructed another new network. Among them, all elements in AC112721.1/LINC00473/AC128709.1‐hsa‐mir‐195‐RECK and LINC00460‐hsa‐mir‐429‐ZFPM2 axes were simultaneously corelated with overall survival. RT‐PCR showed that AKAP12 was downregulated in tumour tissues. The hub genes screened out in the present study may provide ideals for further treatment on BTCC.
- 5 October 2023
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 28 (5)
Open AccessIdentification of hub genes in bladder transitional cell carcinoma through ceRNA network construction integrated with gene network analysis
Bladder transitional cell carcinoma (BTCC) forms more than 90% of bladder cancer cases. It brings challenges to the early diagnosis and therapy of BTCC, due to lack of efficient screening biomarkers. We used weighted gene co‐expression network analysis (WGCNA) combined competing endogenous RNA (ceRNA) network construction depending on TCGA datasets to investigate potential hub genes and regulatory pathways associated with occurrence and progression of BTCC. We further used real‐time polymerase chain reaction (RT‐PCR) to validate the relative expression genes correlated with BTCC. By WGCNA, the gene co‐expression module with 11 genes was found corelated with BTCC tumour stage and prognosis after survival analyses. Ultimately, we put 100 highly stage‐related genes into the above constructed ceRNA network and then constructed another new network. Among them, all elements in AC112721.1/LINC00473/AC128709.1‐hsa‐mir‐195‐RECK and LINC00460‐hsa‐mir‐429‐ZFPM2 axes were simultaneously corelated with overall survival. RT‐PCR showed that AKAP12 was downregulated in tumour tissues. The hub genes screened out in the present study may provide ideals for further treatment on BTCC.
- Open Access
- 1 January 2023
- Published by Knowledge Enterprise Journals in Medical Research Archives
- Vol. 11 (8)
The Association between IL10 rs1800896 A/G and rs1800871 T/C Polymorphisms and Cancer Susceptibility
Background: The significance of interleukin-10(IL-10) on the susceptibility of malignant tumor is one of the hot spots of current research. 1082A > G (rs1800896) and -819C > T (rs1800871) are two genetic variants of IL-10, and their effects on malignancy need to be further explored. Therefore, in order to further explore the relationship between IL-10 polymorphisms and cancer susceptibility and the role of IL-10 in the occurrence and development of malignant tumors, in this paper, we use of odds ratios (ORs), corresponding 95% confidence intervals (CIs), and in silico tools. analysis to study the relationship between the two. Furthermore, GSEA was used to analyze the expression of IL-10 in renal cell carcinoma, bladder cancer and prostate cancer. We conducted a systematic analysis of 50 controlled trials involving 15,418 cancer patients and 18,597 controls. The analysis showed that the -1082A>G (rs1800896) and -819C>T (rs1800871) polymorphism were associated with the risk of bladder cancer. GSEA showed that IL-10 was highly expressed through the Cytokine-Cytokine-receptor-interaction pathway, JSK-STAT-signaling pathway, Natural killer cell mediated cytotoxicity pathway and Leukocyte transendothelial migration pathway.
- 1 January 2023
- Published by Knowledge Enterprise Journals in Medical Research Archives
- Vol. 11 (8)
Open AccessThe Association between IL10 rs1800896 A/G and rs1800871 T/C Polymorphisms and Cancer Susceptibility
Background: The significance of interleukin-10(IL-10) on the susceptibility of malignant tumor is one of the hot spots of current research. 1082A > G (rs1800896) and -819C > T (rs1800871) are two genetic variants of IL-10, and their effects on malignancy need to be further explored. Therefore, in order to further explore the relationship between IL-10 polymorphisms and cancer susceptibility and the role of IL-10 in the occurrence and development of malignant tumors, in this paper, we use of odds ratios (ORs), corresponding 95% confidence intervals (CIs), and in silico tools. analysis to study the relationship between the two. Furthermore, GSEA was used to analyze the expression of IL-10 in renal cell carcinoma, bladder cancer and prostate cancer. We conducted a systematic analysis of 50 controlled trials involving 15,418 cancer patients and 18,597 controls. The analysis showed that the -1082A>G (rs1800896) and -819C>T (rs1800871) polymorphism were associated with the risk of bladder cancer. GSEA showed that IL-10 was highly expressed through the Cytokine-Cytokine-receptor-interaction pathway, JSK-STAT-signaling pathway, Natural killer cell mediated cytotoxicity pathway and Leukocyte transendothelial migration pathway.
- Open Access
- 5 December 2022
- Published by Wiley in Cancer Medicine
- Vol. 12 (6) , 7149-7163
NUPR1 imparts oncogenic potential in bladder cancer
Background: NUPR1, or p8, is a small chromatin protein that plays a central role in the resistance to treatment and progression of cancer. Nevertheless, the molecular mechanism of NUPR1 in bladder cancer (BLCA) remains unclear.Methods: We used online databases and immunohistochemistry (IHC) to explore the expression of NUPR1 in BLCA tissues and controls. Lentivirus‐mediated small interfering ribonucleic acid (siRNA) was used to knockdown the expression of NUPR1 in two human BLCA cell lines. We used an in vivo experiment to investigate the effect of NUPR1 knockdown on the growth of BLCA. Moreover, an in silico analysis was conducted to assess the differential expression profile after NUPR1 interference. The CIBERSORT algorithm was utilized to evaluate the effects of tumor‐infiltrating immune cells among BLCA patients.Results: The expression of NUPR1 in BLCA tissues was significantly higher than in the control. NUPR1 expression was also positively correlated with the stage of BLCA. After lentivirus‐mediated interference, the expression of NUPR1 was significantly down‐regulated in BLCA cell lines. The cell cycle was blocked in G1 phase and the cell proportion of S phase was decreased in both two cell lines. Moreover, in vivo experiment revealed that the tumor growth of BLCA can be delayed by inhibiting the expression of NUPR1. Both in silico analysis and functional experiments revealed that NUPR1 was correlated with epithelial–mesenchymal transition (EMT). We also revealed that macrophages were the most related immune cells associated with the expression of NUPR1 in BLCA.Conclusions: This study suggests that NUPR1 plays a carcinogenic role in BLCA. NUPR1 lentivirus‐mediated interference could interfere with cycle progression of the BLCA cell, resulting in cell cycle arrest in the G1‐phase. The carcinogenic effect of NUPR1 in BLCA is likely achieved through EMT. NUPR1 is correlated with the M0‐type macrophage markers CD68 and CD11b‐integrin.
- 5 December 2022
- Published by Wiley in Cancer Medicine
- Vol. 12 (6) , 7149-7163
Open AccessNUPR1 imparts oncogenic potential in bladder cancer
Background: NUPR1, or p8, is a small chromatin protein that plays a central role in the resistance to treatment and progression of cancer. Nevertheless, the molecular mechanism of NUPR1 in bladder cancer (BLCA) remains unclear.Methods: We used online databases and immunohistochemistry (IHC) to explore the expression of NUPR1 in BLCA tissues and controls. Lentivirus‐mediated small interfering ribonucleic acid (siRNA) was used to knockdown the expression of NUPR1 in two human BLCA cell lines. We used an in vivo experiment to investigate the effect of NUPR1 knockdown on the growth of BLCA. Moreover, an in silico analysis was conducted to assess the differential expression profile after NUPR1 interference. The CIBERSORT algorithm was utilized to evaluate the effects of tumor‐infiltrating immune cells among BLCA patients.Results: The expression of NUPR1 in BLCA tissues was significantly higher than in the control. NUPR1 expression was also positively correlated with the stage of BLCA. After lentivirus‐mediated interference, the expression of NUPR1 was significantly down‐regulated in BLCA cell lines. The cell cycle was blocked in G1 phase and the cell proportion of S phase was decreased in both two cell lines. Moreover, in vivo experiment revealed that the tumor growth of BLCA can be delayed by inhibiting the expression of NUPR1. Both in silico analysis and functional experiments revealed that NUPR1 was correlated with epithelial–mesenchymal transition (EMT). We also revealed that macrophages were the most related immune cells associated with the expression of NUPR1 in BLCA.Conclusions: This study suggests that NUPR1 plays a carcinogenic role in BLCA. NUPR1 lentivirus‐mediated interference could interfere with cycle progression of the BLCA cell, resulting in cell cycle arrest in the G1‐phase. The carcinogenic effect of NUPR1 in BLCA is likely achieved through EMT. NUPR1 is correlated with the M0‐type macrophage markers CD68 and CD11b‐integrin.
- 1 April 2022
- Published by Springer Nature in Biochemical Genetics
- Vol. 60 (6) , 2327-2345
circ3323 Motivates Host Gene to Promote the Aggressiveness of Bladder Cancer
Bladder cancer (BCa) is the most common cancer in the urinary system with high recurrence rate and poor prognosis. Circular RNA (circRNA) is a novel subclass of noncoding-RNA which participate in progression of BCa. Here, we identified a novel circRNA–circ3323 and aimed to investigate the role of circ3323 in progression of BCa. Public data of RNA sequencing was used to identify significant circRNA related to BCa. The role of circRNAs in progression of BCa was assessed in cytotoxicity assay, transwell assay and flow cytometry. Biotin-coupled RNA pull-down and fluorescence in situ hybridization were performed to evaluate the interaction between circRNAs and miRNAs. The expression of circ3323 was higher in BCa tissues and cells than in normal samples. Experiments in vitro showed that the knockdown of circ3323 inhibited cell proliferation and impeded the metastasis of BCa cells. Mechanistically, we demonstrated that circ3323 acts as a sponge for miR-186-5p and promotes host gene APP’s expression. Clinically, circ3323 predicts worse overall survival of BCa patients, indicating its prognostic value. Our study identified that circ3323 modulates metastasis of BCa through miR-186-5p/APP axis and may serve as a promising prognostic biomarker for BCa, which provides novel insights into treatment of BCa.
- 1 April 2022
- Published by Springer Nature in Biochemical Genetics
- Vol. 60 (6) , 2327-2345
circ3323 Motivates Host Gene to Promote the Aggressiveness of Bladder Cancer
Bladder cancer (BCa) is the most common cancer in the urinary system with high recurrence rate and poor prognosis. Circular RNA (circRNA) is a novel subclass of noncoding-RNA which participate in progression of BCa. Here, we identified a novel circRNA–circ3323 and aimed to investigate the role of circ3323 in progression of BCa. Public data of RNA sequencing was used to identify significant circRNA related to BCa. The role of circRNAs in progression of BCa was assessed in cytotoxicity assay, transwell assay and flow cytometry. Biotin-coupled RNA pull-down and fluorescence in situ hybridization were performed to evaluate the interaction between circRNAs and miRNAs. The expression of circ3323 was higher in BCa tissues and cells than in normal samples. Experiments in vitro showed that the knockdown of circ3323 inhibited cell proliferation and impeded the metastasis of BCa cells. Mechanistically, we demonstrated that circ3323 acts as a sponge for miR-186-5p and promotes host gene APP’s expression. Clinically, circ3323 predicts worse overall survival of BCa patients, indicating its prognostic value. Our study identified that circ3323 modulates metastasis of BCa through miR-186-5p/APP axis and may serve as a promising prognostic biomarker for BCa, which provides novel insights into treatment of BCa.
- Open Access
- 17 January 2022
- Published by Hindawi Limited in Disease Markers
- Vol. 2022, 1-16
Associations of Genetic Polymorphisms of mTOR rs2295080 T/G and rs1883965 G/A with Susceptibility of Urinary System Cancers
Background. Genetic polymorphisms in mammalian target of rapamycin (mTOR) signaling axis can influence the susceptibility of cancer. The relationship between mTOR gene variants rs2295080 T/G and rs1883965 G/A and the risk of cancer remains inconsistent. The present study is aimed at comprehensively investigating the association between mTOR polymorphisms and susceptibility to cancer. Methods. We conducted a comprehensive assessment using odds ratios (ORs), corresponding 95% confidence intervals (CIs), and in silico tools to evaluate the effect of mTOR variations. Immunohistochemical staining (IHS) and GSEA analysis were used to investigate the expression of mTOR in urinary system cancer. Results. The pooled analysis involved 22 case-control studies including 14,747 cancer patients and 16,399 controls. The rs2295080 T/G polymorphism was associated with the risk of cancer (G-allele versus T-allele, , –0.98, ; GT versus TT, , –0.96, ; GG+GT versus TT, , –0.96, ), especially for cancers of the urinary system, breast, and blood. Variation rs1883965 G/A was associated with cancer susceptibility, especially for digestive cancer. IHS analysis showed that mTOR was upregulated in prostate and bladder cancer. GSEA revealed that the insulin signaling pathway, lysine degradation pathway, and mTOR signaling pathway were enriched in the high mTOR expression group. Conclusions. The mTOR rs2295080 T/G polymorphism may be associated with susceptibility of urinary cancer. The expression of mTOR is positively correlated with tumor malignancy in prostate cancer.
- 17 January 2022
- Published by Hindawi Limited in Disease Markers
- Vol. 2022, 1-16
Open AccessAssociations of Genetic Polymorphisms of mTOR rs2295080 T/G and rs1883965 G/A with Susceptibility of Urinary System Cancers
Background. Genetic polymorphisms in mammalian target of rapamycin (mTOR) signaling axis can influence the susceptibility of cancer. The relationship between mTOR gene variants rs2295080 T/G and rs1883965 G/A and the risk of cancer remains inconsistent. The present study is aimed at comprehensively investigating the association between mTOR polymorphisms and susceptibility to cancer. Methods. We conducted a comprehensive assessment using odds ratios (ORs), corresponding 95% confidence intervals (CIs), and in silico tools to evaluate the effect of mTOR variations. Immunohistochemical staining (IHS) and GSEA analysis were used to investigate the expression of mTOR in urinary system cancer. Results. The pooled analysis involved 22 case-control studies including 14,747 cancer patients and 16,399 controls. The rs2295080 T/G polymorphism was associated with the risk of cancer (G-allele versus T-allele, , –0.98, ; GT versus TT, , –0.96, ; GG+GT versus TT, , –0.96, ), especially for cancers of the urinary system, breast, and blood. Variation rs1883965 G/A was associated with cancer susceptibility, especially for digestive cancer. IHS analysis showed that mTOR was upregulated in prostate and bladder cancer. GSEA revealed that the insulin signaling pathway, lysine degradation pathway, and mTOR signaling pathway were enriched in the high mTOR expression group. Conclusions. The mTOR rs2295080 T/G polymorphism may be associated with susceptibility of urinary cancer. The expression of mTOR is positively correlated with tumor malignancy in prostate cancer.